

Technology Advisory Interests Register

Topic: Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over

[ID6342]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor David Meads	TAC Committee member	Non-financial - Professional	Professor Meads works for the University of Leeds, who have received funding from Takeda for research in an unrelated area.	23/11/2024	It was agreed that Professor Meads' declaration would not prevent them from participating in discussions on this appraisal.
Becky Pennington	TAC Committee member	Direct - Financial	Becky has taken consultancy fees from Roche & Takeda for methods research around unpaid carers, not related to this disease and not specific to any intervention.	26/11/2024	It was agreed that Becky's declaration would not prevent them from participating in discussions on this appraisal.
Mary Mathias	Clinical Expert	Direct – Financial	Mary declared the following financial interests: • Paid Member of Advisory Board for Sobi in relation to a FVIII concentrate (£4050) • Paid speaker for Octapharma (most recently	05/12/2024 12/03/2025	It was agreed that Mary's declaration would not prevent them from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Mary Mathias	Clinical Expert	Direct – non-	in 2021) and NovoNordisk (£420) • Supported to attend meetings by Octapharma, NovoNordisk and Roche Mary declared the following non-	05/12/2024	It was agreed that Mary's
mary manage	Gillinoui Zapon	financial	financial interests: Principal or subinvestigator in IMP and non-interventional trials for NovoNordisk, Roche, Sanofi and Octapharma Secretary to the UKHCDO (United Kingom Haemophilia Centre Directors Organisation) Chair to the UKHCDO Paediatric Working Party Member of the Medical and Scientific Advisory Group for the UK Haemophilia Society	12/03/2025	declaration would not prevent them from providing expert advice to the committee.
Charles Percey	Clinical Expert	Direct – Financial	Charles declared the following financial interests: Paid speaker fees, Sobi, 14th November 2023 and 29th August 2024, total value £1800.	05/12/2024 12/03/2025	It was agreed that Charles' declaration would not prevent them from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Jefferson Courtney	Patient Expert	Direct – non- financial	Jefferson is an employee of the Haemophilia Society which receives some of the funding for its work from the companies listed above.	05/12/2024	It was agreed that Jefferson's declaration would not prevent them from providing expert advice to the committee.